Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) study

Trial Profile

The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) study

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Fenofibrate (Primary) ; Metformin
  • Indications Hypertriglyceridaemia; Insulin resistance; Metabolic syndrome
  • Focus Therapeutic Use
  • Acronyms FAMA
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 15 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 06 Dec 2007 The expected completion date for this trial is now 1 Nov 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top